filmov
tv
Fluciclovine (18F) PET/CT Impact on Clinical Management of Recurrent Prostate Cancer
Показать описание
Phillip J. Koo, MD, discusses conventional prostate cancer imaging techniques and the need for advanced imaging techniques in order to better detect recurrent disease. He then argues that fluciclovine (18F) positron emission tomography/computed tomography (PET/CT) could satisfy this unmet need.
0:26:54
Fluciclovine (18F) PET/CT Impact on Clinical Management of Recurrent Prostate Cancer
0:04:43
FALCON: Impact of 18F-fluciclovine PET/CT on management of biochemically recurrent prostate cancer
0:04:55
18F-fluciclovine PET in mCRPC treated with abiraterone acetate
0:03:28
Fluorine-18 FACBC vs. Gallium-labelled PSMA-11 PET/CT for prostate cancer screening
0:23:23
When, and When Not, to Use PET/CT Part 2
0:04:28
PSMA vs AXUMIN PET/CT in prostate cancer
0:16:45
Imaging With Fluciclovine for Prostate Cancer
0:08:59
PET Imaging for Prostate Cancer
0:04:42
PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients with prostate cancer
0:03:23
FALCON: radiopharmaceuticals for the management of recurrent prostate cancer
0:00:09
18F-FDG PET with CT in patient 5: video 2 of 2
0:03:13
18F-DCFPyL PET/CT imaging up-stages patients with prostate cancer
0:07:42
CONDOR: 18F-DCFPyL PET/CT imaging in suspected reccuring prostate cancer
0:32:05
2021: PSMA and Prostate Imaging | Dr. Thomas Hope | 2021 Moyad + Scholz Mid-Year Update | PCRI
0:01:24
The impact of novel imaging techniques on salvage radiotherapy decisions
0:02:58
AXUMIN
0:12:45
The Role of Molecular Imaging to Improve Cancer Control Post-Prostatectomy
0:10:35
Considerations for the Clinical Impact of Next-Generation Imaging in Prostate Cancer
0:57:22
Urowebinar: PET in Prostate Cancer Evaluation
1:54:40
IPCSG October 2017 Dr Almeida
0:01:20
Prostate cancer: novel tracers in choline PET/CT
0:01:26
Dr. Choyke on Differences Between PET Scans in Prostate Cancer
0:29:35
Molecular PSMA Imaging and Targeted Radionuclide Therapy of Metastatic Prostate Cancer
0:10:01
Evaluating the prognostic value of PSMA PET/CT in mCRPC
Комментарии